S&P 500

6.021,63

0,57%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Eli Lilly and Co (LLY)
Eli Lilly and Co (LLY) Notícias

LLY

Eli Lilly (LLY)

Eli Lilly and Co

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NYSE:LLY

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
20/11/2024	18:29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:LLY	Eli Lilly and Co
20/11/2024	07:00	GlobeNewswire Inc.	Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS	NYSE:LLY	Eli Lilly and Co
19/11/2024	18:49	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:LLY	Eli Lilly and Co
19/11/2024	18:30	PR Newswire (US)	Lilly announces changes on board of directors	NYSE:LLY	Eli Lilly and Co
18/11/2024	16:52	PR Newswire (US)	Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose	NYSE:LLY	Eli Lilly and Co
16/11/2024	12:00	PR Newswire (US)	Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity	NYSE:LLY	Eli Lilly and Co
14/11/2024	21:00	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NYSE:LLY	Eli Lilly and Co
13/11/2024	19:05	PR Newswire (US)	Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks	NYSE:LLY	Eli Lilly and Co
08/11/2024	18:54	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:LLY	Eli Lilly and Co
05/11/2024	11:04	PR Newswire (US)	Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting	NYSE:LLY	Eli Lilly and Co
01/11/2024	18:30	PR Newswire (US)	Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium	NYSE:LLY	Eli Lilly and Co
30/10/2024	12:54	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:LLY	Eli Lilly and Co
30/10/2024	07:45	PR Newswire (US)	Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products	NYSE:LLY	Eli Lilly and Co
30/10/2024	07:37	IH Market News	US Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge Up	NYSE:LLY	Eli Lilly and Co
29/10/2024	13:15	PR Newswire (US)	Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study	NYSE:LLY	Eli Lilly and Co
28/10/2024	12:31	PR Newswire (US)	Lilly declares fourth-quarter 2024 dividend	NYSE:LLY	Eli Lilly and Co
28/10/2024	07:45	PR Newswire (US)	Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease	NYSE:LLY	Eli Lilly and Co
28/10/2024	07:09	IH Market News	Philips Sales Forecast Cut Sparks Stock Plunge; BP Resumes Libya Exploration; Alibaba Settles for $433 Million	NYSE:LLY	Eli Lilly and Co
25/10/2024	07:45	PR Newswire (US)	Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab	NYSE:LLY	Eli Lilly and Co
23/10/2024	06:00	PR Newswire (US)	Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers	NYSE:LLY	Eli Lilly and Co
22/10/2024	07:04	IH Market News	HSBC Begins Major Restructuring; SAP’s Cloud Revenue Grows 25%; Logitech Shares Drop 7.3% Pre-Market	NYSE:LLY	Eli Lilly and Co
16/10/2024	11:00	PR Newswire (US)	Lilly confirms date and conference call for third-quarter 2024 financial results announcement	NYSE:LLY	Eli Lilly and Co
16/10/2024	08:30	PR Newswire (US)	Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies	NYSE:LLY	Eli Lilly and Co
14/10/2024	07:45	PR Newswire (US)	Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease	NYSE:LLY	Eli Lilly and Co
10/10/2024	07:45	IH Market News	Tesla’s Robotaxi Day; GSK Settles 93% of Zantac Lawsuits; 10x Genomics Stock Drops on Revenue Forecast	NYSE:LLY	Eli Lilly and Co
02/10/2024	10:00	InvestorsHub NewsWire	Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition	NYSE:LLY	Eli Lilly and Co
02/10/2024	08:30	PR Newswire (US)	Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials	NYSE:LLY	Eli Lilly and Co
25/09/2024	07:45	PR Newswire (US)	New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis	NYSE:LLY	Eli Lilly and Co
24/09/2024	07:00	PR Newswire (US)	Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease	NYSE:LLY	Eli Lilly and Co
18/09/2024	17:19	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NYSE:LLY	Eli Lilly and Co